Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
of patient enrollment for its Phase 3 liMeliGhT clinical trial. The trial is for evaluating OCU400, an investigational modifier gene therapy for retinitis pigmentosa, or RP. RP is a hereditary blinding disease. Ocugen Inc. (OCGN) Advances OCU400 Gene Therapy Toward 2027 Approval According to Ocugen, the enrollment completion marks the transition from recruitment into the final phase of the trial ahead of a targeted 2027 approval. The trial enrolled 140 patients, randomized at a 2:1 ratio into a treatment group and an untreated control group, the company detailed. It added that the trial covers a broad range of RP gene mutations. OCU400 is administered as a single injection per eye, Ocugen stated. The treatment works by targeting the NR2E3 nuclear hormone receptor gene, which regulates multiple retinal functions including photoreceptor development and cell survival. Rather than correcting a single mutation, Ocugen explained, the treatment aims to restore a dysfunctional gene netw
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]TheStreet.com
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGlobeNewswire
- Ocugen (OCGN) Reveals OCU410 Clinical Trial Data [Yahoo! Finance]Yahoo! Finance
- How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/27/26 - Form 8-K
- 3/24/26 - Form 8-K
- OCGN's page on the SEC website